Leukemia

ANDA approvals in 2002 will lead to four launches in 2003

Published in Cancer Weekly, January 21st, 2003

American Pharmaceutical Partners, APP, (APPX), announced that it has received approvals from the U.S. Food and Drug Administration (FDA) for the Abbreviated New Drug Applications (ANDAs) of vincristine sulfate injection, USP, the generic equivalent of Oncovin marketed by Eli Lilly and Company, and kanamycin sulfate, USP, the generic equivalent of Kantrex marketed by Geneva Pharmaceuticals.

APP expects to begin marketing vincristine as well as kanamycin in 2003.

"Vincristine and kanamycin add further breadth to our oncology and anti-infective product offerings and brings to 12 the number of FDA approvals APP has received in 2002," said Patrick...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-01-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry